{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:52:26Z","timestamp":1788558746598,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009980","name":"Medizinische Universit\u00e4t Innsbruck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtct.2025.09.036","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:42:33Z","timestamp":1758710553000},"page":"182-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Remission Status Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia\/Myelodysplastic Syndrome Patients Harboring Single-Hit or Multi-Hit p53 Mutations Does Not Impact Outcome"],"prefix":"10.1016","volume":"32","author":[{"given":"Normann","family":"Steiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Klyuchnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Badbaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwan","family":"Massoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaby","family":"Zeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherina","family":"Lueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Ayuketang","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtct.2025.09.036_bib0001","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.036_bib0002","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.036_bib0003","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jtct.2025.09.036_bib0004","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.036_bib0005","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.036_bib0006","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jtct.2025.09.036_bib0007","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.036_bib0008","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2025.09.036_bib0009","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol."},{"issue":"9","key":"10.1016\/j.jtct.2025.09.036_bib0010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/bmt.2009.359","article-title":"Regression modeling of competing risk using R: an in-depth guide for clinicians","volume":"45","author":"Scrucca","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"446","key":"10.1016\/j.jtct.2025.09.036_bib0011","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.036_bib0012","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","article-title":"Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"37","author":"Badar","year":"2023","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.036_bib0013","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.3390\/cancers15123210","article-title":"TP53 Mutations in AML patients are associated with dismal clinical outcome irrespective of frontline induction regimen and allogeneic hematopoietic cell transplantation","volume":"15","author":"Zhao","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.036_bib0014","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.jtct.2025.09.036_bib0015","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.036_bib0016","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood.2022018236","article-title":"TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype","volume":"141","author":"Hiwase","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.036_bib0017","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.036_bib0018","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-Mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.036_bib0019","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","article-title":"Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment","volume":"116","author":"Kreidieh","year":"2022","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.036_bib0020","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41375-022-01766-z","article-title":"Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy","volume":"37","author":"Zeidan","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.036_bib0021","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am J Hematol"},{"issue":"28","key":"10.1016\/j.jtct.2025.09.036_bib0022","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","article-title":"Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study","volume":"41","author":"Versluis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jtct.2025.09.036_bib0023","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2024015335","article-title":"Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations","volume":"9","author":"Baranwal","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.036_bib0024","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/17474086.2020.1804355","article-title":"Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation","volume":"13","author":"Baek","year":"2020","journal-title":"Expert Rev Hematol."},{"issue":"34","key":"10.1016\/j.jtct.2025.09.036_bib0025","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.09.036_bib0026","unstructured":"Aprea Therapeutics. Aprea Therapeutics announces results of primary endpoint from phase 3 trial of Eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS). Global Newswire. December 28, 2020."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:23:22Z","timestamp":1771374202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666636725014630"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.036","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remission Status Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia\/Myelodysplastic Syndrome Patients Harboring Single-Hit or Multi-Hit p53 Mutations Does Not Impact Outcome","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}